Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arjo ABARRJF -0.34%74 Debt-to-Equity is 0.17 as of Jun. 2026, which is 11% below its 10-year median of 0.19. GuruFocus rates ARRJF with a GF Score™ of 74/100 and a GF Value™ of $3.51 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 99 Medical Distribution companies, Arjo AB ranks better than 69.7% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Arjo AB's Debt-to-Equity or its related term are showing as below:
ARRJF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.19 Max: 1.05
Current: 0.17
During the past 13 years, the highest Debt-to-Equity Ratio of Arjo AB was 1.05. The lowest was 0.03. And the median was 0.19.
ARRJF's Debt-to-Equity is ranked better than 69.7% of 99
companies
in the Medical Distribution industry
Industry Median: 0.48
vs ARRJF: 0.17
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Arjo AB Debt-to-Equity Related Terms
Arjo AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Arjo AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Arjo AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Arjo AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arjo AB (ARRJF) has a Debt-to-Equity of 0.17 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Arjo AB and its competitors. This is 11% below median its historical median of 0.19. Over the past decade, Arjo AB's Debt-to-Equity has ranged from 0.03 to 1.05. According to the industry distribution chart, Arjo AB ranks #30 out of 99 companies in the Medical Distribution industry, placing it in the top 30.3%.
Is Arjo AB's Debt-to-Equity too high?
Arjo AB's current Debt-to-Equity of 0.17 is 11% below median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 1.05. The Medical Distribution industry median Debt-to-Equity is 0.48. Arjo AB's value of 0.17 is 64.6% below this industry median. Based on the distribution chart, Arjo AB ranks #30 out of 99 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Arjo AB has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #30 out of 99 companies for Debt-to-Equity. This puts Arjo AB in the upper half of its industry. The industry median Debt-to-Equity is 0.48. Arjo AB's value of 0.17 is 64.6% below this benchmark. Historically, Arjo AB's own Debt-to-Equity has ranged from 0.03 to 1.05 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 0.48, Arjo AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arjo AB's current Debt-to-Equity of 0.17 is 64.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Arjo AB and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current Debt-to-Equity is 0.17, which is 11% below median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (ARRJF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.51, compared to a current price of $2.91 — trading 17.1% below its estimated fair value. The current Debt-to-Equity is 0.17, which is 11% below median its 10-year median of 0.19 and 64.6% below the Medical Distribution industry median of 0.48. Arjo AB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Arjo AB (ARRJF), the current Debt-to-Equity is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (ARRJF) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of $2.91 is trading 17.1% below its estimated GF Value™ of $3.51.
GuruFocus considers Arjo AB to be Modestly Undervalued.
Key valuation signals for ARRJF:
Debt-to-Equity: 0.17 (11% below median its 10-year median of 0.19)
GF Value™: $3.51 vs. price of $2.91 (17.1% below fair value)
Industry Position: 64.6% below the Medical Distribution median (#30 of 99)
No single metric tells the full story. See the ARRJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
74GF Score
Get the complete analysis for ARRJF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARRJF has been successfully added to your 
